SLU-PP-332

Plain-English version: SLU-PP-332 is a small synthetic molecule designed to flip on the same genetic "exercise switches" your muscles use during a hard aerobic workout — the programs that build mitochondria (your cells' power plants) and ramp up fat burning. The dream researchers are chasing is a pill that delivers some of the metabolic benefits of exercise to people who cannot exercise, such as patients with heart failure or muscle-wasting disease.

The name comes from Saint Louis University, where the compound was created. It was developed in the laboratory of Dr. Thomas P. Burris (who has since moved his research program to the University of Florida and collaborates with Scripps), and the lead first author on the foundational papers is Cyrielle Billon.^[1] A quick but important correction for anyone who has read otherwise online: the compound was not developed by a "Dr. Bhullar," and it is not the subject of any Journal of Biological Chemistry paper — those are errors that have circulated in secondhand write-ups.

One more foundational point, because it changes how you should think about everything below: SLU-PP-332 is not a peptide. A peptide is a short chain of amino acids; SLU-PP-332 is a conventional small-molecule drug candidate. We cover it here because it targets the same metabolic terrain — fat oxidation, energy expenditure, muscle performance — as many of the peptides our readers research, and because it is sold through the same gray-market "research chemical" channels.

The credibility caveat, stated up front: the excitement around SLU-PP-332 rests entirely on mouse and cell-culture experiments. There are no human trials, no published human pharmacokinetics (how it is absorbed and cleared in people), and no approved human formulation anywhere in the world. It is sold only as a "research chemical, not for human consumption." For the broader legal picture, see Are Peptides Legal?

Takeaway first: SLU-PP-332 works by activating a family of receptors called estrogen-related receptors (ERRs). Despite the name, these have little to do with estrogen — they are "orphan" nuclear receptors that act as master dials for how much energy a cell can produce. Turning them up mimics the transcriptional (gene-activity) response your body mounts during aerobic exercise.

1. Pan-agonism of ERRα, ERRβ, and ERRγ (the core mechanism)

SLU-PP-332 is a pan-agonist — meaning it activates all three ERR subtypes (alpha, beta, and gamma) rather than just one. ERRs sit at the top of the pathway that governs mitochondrial biogenesis (building new cellular power plants), fatty-acid oxidation (burning fat for fuel), and the programming of oxidative muscle fibers (the fatigue-resistant fiber type endurance athletes prize). Billon and colleagues showed that dosing SLU-PP-332 into mice reproduced the acute transcriptional signature of a bout of aerobic exercise.^[1] Evidence level: cell assays plus mice.

2. The ERRα dependence — proven with a knockout

The most convincing mechanistic evidence is a genetic control experiment. When researchers deleted the ERRα gene in mice (an "ERRα-knockout"), SLU-PP-332's endurance benefit disappeared.^[1] That tells you the effect is genuinely running through ERRα rather than some off-target coincidence — a stronger standard of proof than most research compounds ever meet.

3. Downstream: mitochondria, fat burning, and fiber type

Once ERRs are activated, the cascade plays out in muscle and other high-energy tissues:

• Mitochondrial function increases: muscle from treated mice showed enhanced mitochondrial capacity, the cellular basis of aerobic stamina.^[1]
• Fat oxidation and energy expenditure rise: in obese mice, the compound increased whole-body fatty-acid burning and total energy expenditure.^[2]
• Muscle fiber programming shifts oxidative: treated mice increased their share of Type IIa oxidative fibers — the fatigue-resistant type that endurance training also promotes.^[1]

What we do NOT know

There is no established human pharmacokinetic profile, no confirmed human tissue distribution, and no human dose-response data. ERRs are expressed all over the body — heart, liver, kidney, reproductive tissue — so activating them everywhere at once could have consequences that mouse studies of a few weeks simply cannot reveal. The mechanisms above are real, well-controlled findings, but they are findings in mice. Mechanism in animals does not guarantee benefit, or safety, in people.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. Every result below is from mice or cells. That does not make it worthless — it makes it preliminary. There are no human outcomes of any kind.

Endurance and exercise capacity

Claim: may increase aerobic stamina without training. Mechanism: ERRα-driven mitochondrial biogenesis and a shift toward oxidative muscle fibers. Population: wild-type mice dosed at 50 mg/kg twice daily by intraperitoneal (into-the-abdomen) injection, tested in one-hour treadmill runs. Effect: treated mice ran farther and longer than controls, with more oxidative fibers and better mitochondrial function; critically, the benefit vanished in ERRα-knockout mice, confirming the mechanism.^[1] Limitation: mouse-only, short-term. A note on the widely-quoted "45–70% endurance increase": that specific range is not confirmed by the primary paper's record, which reports increased distance and time without pinning those exact percentages. Treat the headline number with skepticism — the honest statement is "endurance improved," not a precise figure. This is the finding that fuels most of the endurance interest in the compound.

Fat loss and metabolic syndrome

Claim: may reduce fat gain and improve blood-sugar control. Mechanism: increased fatty-acid oxidation and energy expenditure via ERR activation. Population: diet-induced-obese (DIO) mice dosed for 28 days, and genetically obese ob/ob mice dosed for 15 days. Effect: SLU-PP-332 raised fat burning and energy expenditure, decreased fat-mass accumulation, and improved insulin sensitivity and glucose tolerance in the obese, high-fat-diet models.^[2] Limitation: rodent obesity models over a few weeks; no human weight-loss or glycemic data exists. Readers weighing this against options with actual human trials should compare it honestly to peptides for fat loss like tirzepatide.

Heart failure (cardiac function)

Claim: may improve heart-pumping function in failing hearts. Mechanism: enhanced cardiac mitochondrial oxidative capacity and fatty-acid use, giving the heart muscle more usable energy. Population: mice with surgically induced pressure overload (a transaortic-constriction, or TAC, heart-failure model), dosed at 25 mg/kg twice daily for six weeks. Effect: SLU-PP-332 significantly improved ejection fraction (the percentage of blood the heart pumps out per beat), reduced fibrosis (scarring), and increased survival — without changing the degree of cardiac hypertrophy.^[3] Limitation: a single mouse heart-failure model; this is a hypothesis for a future drug, not evidence that anyone should take SLU-PP-332 for a heart condition.

Aging kidney and mitochondrial health

Claim: may reverse age-related decline in mitochondrial function and inflammation. Mechanism: ERR agonism restoring mitochondrial gene programs. Population: aging mice, kidney tissue. Effect: ERR agonism with SLU-PP-332 reversed mitochondrial dysfunction and reduced inflammation in the aging mouse kidney.^[4] Limitation: a single-organ aging model in mice; no human relevance is established.

The honest bottom line on "benefits"

• No human trials have been conducted. Human pharmacokinetics, effective doses, and any real-world benefit are entirely unknown.
• The research is young and concentrated. The core body of work comes from one laboratory over a short span (2023–2024); independent replication is still thin.
• Publication bias means positive mouse results reach print more readily than null ones.
• Anecdotes are not data. Online reports of endurance gains cannot substitute for controlled trials that do not yet exist.

Read this first: there is no human dose for SLU-PP-332 — none has ever been established, because no human study has ever been run. Every published dose is in mice, given by intraperitoneal injection (into the abdominal cavity), a route that is not used in normal human medicine. We describe the research doses for completeness and context, not as guidance, and we want to be explicit that no safe or effective human dose exists.

Published research doses (mice only)

Model	Dose	Frequency	Route	Duration
Endurance / exercise capacity	50 mg/kg	Twice daily	Intraperitoneal	Days to weeks[1]
Diet-induced obesity	Per protocol	Daily	Intraperitoneal	28 days[2]
ob/ob metabolic model	Per protocol	Daily	Intraperitoneal	15 days[2]
Heart failure (TAC)	25 mg/kg	Twice daily	Intraperitoneal	6 weeks[3]

A correction worth flagging: some secondhand write-ups cite a "10–50 mg/kg" mouse range. The verified papers do not support a 10 mg/kg lower bound — the principal doses are 50 mg/kg twice daily (endurance) and 25 mg/kg twice daily (cardiac). If a source quotes a number, check it against the primary paper.

Why you cannot simply "convert" a mouse dose

People often try to scale animal doses to humans using allometric (body-surface-area) math. That math exists, but applying it here would be misleading for two reasons. First, the studies used intraperitoneal injection, a route with different absorption than anything a person would use. Second — and more importantly — dose scaling only tells you a starting point for a formal safety study; it says nothing about whether a compound is safe or effective in humans. With zero human pharmacokinetic or toxicology data, any "human equivalent dose" for SLU-PP-332 is a fiction. There is no worked reconstitution example to give here that would be responsible, because there is no validated human protocol to reconstitute toward.

Oral potential (theoretical)

As a small molecule rather than a peptide, SLU-PP-332 could in principle be developed as an oral drug — small molecules generally survive digestion better than peptides do. But "could in principle" is doing heavy lifting: no orally optimized, pharmacokinetically characterized human formulation has been published. The research material sold online has not been through any of the formulation work a real oral medicine requires.

Study duration and timing

• Duration in mice: benefits appeared over windows of roughly two to six weeks depending on the model.
• Timing: the twice-daily dosing in the key studies reflects the compound's short action in mice, not a validated human schedule.

None of the above should be read as a protocol to follow. It is a description of how the animal research was structured, provided so you can interpret the literature accurately.

Straight talk: there is no dedicated toxicology study and no human safety data for SLU-PP-332 at all. The short mouse studies did not report obvious toxicity over their durations, but "no toxicity noticed in a 2–6 week mouse experiment" is a long way from "safe in humans." Treat the safety section below as a list of open questions, not a reassurance.

What the animal studies observed

Observation	Context	Interpretation
No overt toxicity reported	Short-duration mouse studies	Reassuring but limited — not a safety study
Reduced weight gain on high-fat diet	Obese mice	A therapeutic effect, not an adverse one[2]
Improved survival	Heart-failure mice	Beneficial in that model[3]

Theoretical risks (hypotheses, not findings)

Because ERRs are active in tissues far beyond skeletal muscle, activating all three subtypes body-wide raises questions that the current literature simply has not answered. These are hypotheses to take seriously, not documented harms:

• Cancer signaling: ERRα in particular has context-dependent roles in some cancers, including breast cancer, where higher ERRα activity has been associated with worse outcomes. Whether a pan-ERR agonist would matter clinically is unquantified — but it is the single most important open safety question.
• Cardiac effects: although SLU-PP-332 helped failing mouse hearts, ERR-driven changes to cardiac metabolism in a healthy heart over years are unstudied.
• Hepatic and reproductive tissue: ERRs are expressed in liver and reproductive organs; chronic activation there has not been characterized.
• No drug-interaction data: nothing is known about how it behaves alongside other medications.

Who should not use it (theoretical contraindications)

• Anyone with active or recent cancer, given the ERR-cancer signaling questions above
• People with cardiac disease outside a monitored study setting
• Pregnant or breastfeeding individuals — no reproductive-safety data exist
• Anyone on other medications, since interactions are entirely uncharacterized

The regulatory signal you should notice

One indirect safety-relevant fact: as of 2026, SLU-PP-332 and its metabolites are being characterized specifically for anti-doping detection.^[5] That means sports and regulatory bodies already treat it as an unapproved performance-enhancing agent worth policing. It does not tell you the compound is dangerous, but it does tell you that serious institutions consider it a real, unapproved drug — not a benign supplement. For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: SLU-PP-332 is sold only as a gray-market "research chemical, not for human consumption." There is no pharmaceutical-grade source, no regulated manufacturing standard, and no oversight of what is actually in the vial. For an unproven compound, contamination and mislabeling are arguably a bigger practical hazard than the molecule itself.

What a more credible product should show

• Third-party Certificate of Analysis (COA): independent HPLC purity testing and mass-spectrometry identity confirmation, referencing the specific batch you are buying.
• Correct identity: a COA should confirm the material is actually SLU-PP-332 and not a mislabeled or substituted compound.
• Batch-specific results: generic or reused certificates are a red flag.
• Sensible packaging: sealed, labeled, protected from light and moisture.

Red flags

• No COA, or a COA issued by the seller rather than an independent lab
• Explicit human-use or medical claims, which mark a non-compliant, higher-risk vendor
• Prices far below the rest of the market
• Pre-dissolved "ready to use" liquid, which raises stability and contamination concerns

Legal and regulatory status (2026)

• Not FDA-approved for any use, and never evaluated by the FDA for any indication. There is no publicly disclosed Investigational New Drug (IND) application or registered clinical trial.
• Sold as a research chemical only — explicitly not for human consumption. Vendors that claim otherwise are non-compliant.
• Anti-doping scrutiny: its metabolites are being characterized for doping control, so competitive athletes should treat it as bannable.^[5]
• Not an approved medicine anywhere in the world at the time of writing.

Storage

Research-grade material is typically stored desiccated (moisture-free) at around -20°C, protected from light, and handled per the supplier's specifications. As with any unregulated compound, the storage instructions on a research vial are only as trustworthy as the vendor behind them. For the complete legal picture, read Are Peptides Legal?

SLU-PP-332 belongs to a long line of "exercise mimetic" candidates. None of these comparisons are backed by head-to-head human trials — they contrast mechanisms and evidence maturity.

SLU-PP-332 vs. older exercise mimetics

Compounds like AICAR (an AMPK activator) and GW501516/"Cardarine" (a PPARδ agonist) chased the same goal a decade earlier. GW501516 is a cautionary tale: it was abandoned after animal studies linked long-term high-dose use to cancer, and it is now banned in sport. SLU-PP-332 works through a different pathway (ERRs rather than PPARδ or AMPK), but the history is a reminder that "activates exercise genes" and "safe for humans" are not the same claim — and that ERRα's own cancer associations deserve the same caution.

SLU-PP-332 vs. metabolic peptides

Many readers arrive comparing SLU-PP-332 to incretin-based fat-loss compounds. The key difference is evidence maturity: peptides like semaglutide, tirzepatide, and retatrutide have large human trials and, in several cases, FDA approval, whereas SLU-PP-332 has zero human data. They also work differently — incretin peptides mainly reduce appetite and food intake, while SLU-PP-332 aims to increase energy expenditure and fat burning. For most goals, the honest recommendation is to weigh a mouse-only compound against options that have actually been tested in people.